BioLIMS 21 CFR Part 11 Compliance White Paper
- Bio LIMS INC
- Oct 9
- 4 min read
1. 🔍 Introduction
In the era of digital transformation in life sciences, laboratories rely on electronic systems to manage data, execute workflows, and ensure product quality.To maintain integrity, authenticity, and traceability of electronic records and signatures, regulatory compliance with FDA 21 CFR Part 11 is a fundamental requirement.
💡 BioLIMS is purpose-built to support laboratories under GxP, GLP, and cGMP environments — ensuring that electronic records and signatures are as reliable and legally binding as paper-based documentation.It provides automation, security, and auditability at every step.
2. 📜 Understanding FDA 21 CFR Part 11
FDA 21 CFR Part 11 defines criteria for when electronic records and signatures are trustworthy, reliable, and equivalent to handwritten ones.
📘 Scope
Part 11 applies to:
💻 Electronic records used in regulated processes (R&D, clinical, manufacturing)
✍️ Electronic signatures replacing handwritten approvals
🗂️ Systems that create, modify, maintain, or transmit such records
🔑 Three Key Pillars
🔒 System Security – Prevent unauthorized access or data tampering
🕓 Audit Trail – Maintain secure, time-stamped, unalterable history
✅ Electronic Signatures – Ensure digital sign-offs are unique, verifiable, and legally binding
3. 🧩 BioLIMS Compliance Framework
BioLIMS integrates Part 11 compliance into both technical architecture and operational controls.The platform is validated following GAMP5 and FDA Software Validation Principles, ensuring full traceability from requirements to deployment.
Regulatory Requirement | BioLIMS Compliance Feature |
🔐 Access Control | Role-based access (RBAC), multi-factor authentication, session timeout |
🧱 System Security | TLS 1.3 encryption, AES-256 data storage, tenant isolation |
🕓 Audit Trail | Immutable logs of all create/edit/delete events with user, timestamp, and reason |
✍️ Electronic Signature | Bound to user ID, password re-verification, cryptographic linkage |
🧬 Data Integrity | Original data preserved; all edits versioned with justification |
🔁 Version Control | Automatic versioning for templates, workflows, SOPs, and reports |
🔄 Change Control | All configuration and software updates validated and documented |
🧾 System Validation | IQ/OQ/PQ protocols with traceability matrix |
💾 Backup & Retention | Automated encrypted backups, configurable retention policies |
🎓 Training & SOPs | Permissions linked to training; audit-ready records |
4. 🧪 Software Validation and Documentation
BioLIMS complies with FDA’s “General Principles of Software Validation” (2002) and GAMP5 best practices.
📄 Validation Deliverables
🗂️ Validation Plan (VP) – Scope, strategy, and responsibilities
📋 User Requirements (URS) – Mapped to 21 CFR Part 11 clauses
⚙️ Functional & Design Specifications (FS/DS)
🧭 Risk Assessment (RA) – Identify and mitigate compliance risks
💻 Installation Qualification (IQ) – Verify proper setup
🧰 Operational Qualification (OQ) – Confirm system operates as intended
📈 Performance Qualification (PQ) – Validate performance under real use
🧾 Validation Summary Report (VSR) – Summarize compliance evidence
🧩 BioLIMS provides a complete Validation Package for client-side User Site Validation per FDA requirements.
5. ☁️ Continuous Compliance and Cloud Infrastructure
BioLIMS runs on a secure, cloud-native architecture tailored for regulated environments.
🚀 Key Features
🌍 Multi-region deployment on AWS / Azure / Google Cloud (US, EU, China options)
🔁 Continuous Validation ensuring all updates remain validated and traceable
⚡ Zero-downtime upgrades with automated regression testing
📜 Audit-ready environments with logs and configuration history retained for inspection
Each update undergoes automated testing, validation review, and documented approval before release.
6. 🤝 Responsibilities: Vendor & User
FDA defines shared responsibility for Part 11 compliance:
Responsibility | Description | Party |
🧠 Software Design & Validation | Develop and validate system; provide documentation | BioLIMS Vendor |
🧩 System Configuration & Usage Validation | Validate within user’s environment (IQ/OQ/PQ) | BioLIMS / User Org. |
🧾 Policies, SOPs & Training | Maintain procedures, control access, document training | User Org. / BioLIMS |
BioLIMS Support Includes:
🧱 Standardized validation templates
📚 Preconfigured SOP samples
🔍 Audit preparation guidance
💬 Compliance consulting services
7. 🧭 Data Integrity and GxP Readiness
BioLIMS is built on ALCOA+ principles:Attributable · Legible · Contemporaneous · Original · Accurate · Complete · Consistent · Enduring · Available
📊 All records — raw data, metadata, audit logs — are tamper-proof and version-controlled.BioLIMS fully supports GxP, GLP, GMP, and GDP operations and integrates with regulated systems via secure APIs with full traceability.
8. 🛡️ Compliance Statement
BioLIMS is developed, validated, and maintained in alignment with:
FDA 21 CFR Part 11
GAMP5
Global Data Integrity Standards
It provides:
🔒 Secure user authentication
🕓 Complete audit trails
✍️ Cryptographically bound electronic signatures
All designed to ensure regulatory-grade compliance.Users remain responsible for their procedures, validation, and site documentation.
9. 🌟 Conclusion
BioLIMS offers a comprehensive, validated, and audit-ready platform for FDA and global compliance.With its cloud-native agility and regulatory precision, BioLIMS enables life science organizations to digitize workflows confidently — maintaining data integrity, security, and validation assurance.
💠 BioLIMS: Compliant · Secure · Ready for Inspection
10. 📚 Appendix — Supporting References
📘 FDA 21 CFR Part 11 — Electronic Records; Electronic Signatures
🧾 FDA Guidance — Part 11, Scope and Application
📄 FDA — General Principles of Software Validation (2002)
🧠 ISPE GAMP5 — Risk-Based Approach to Compliant GxP Systems (2nd Ed., 2022)
🧩 EMA Annex 11 — Computerised Systems
🌐 ISO 27001 · ISO 9001 · ISO 13485
Comments